Company news
Actuate Therapeutics, Inc. news in 2024
Actuate Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
December 16, 2024
Actuate Therapeutics to be Added to Russell 2000® Index
November 25, 2024
Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma
November 11, 2024
Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor
September 22, 2024
Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research
September 15, 2024
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
September 10, 2024
Decks in 2024
- Investor Presentation (December 2024)
Investor deck · 23 slides · December 2024
- Investor Presentation (November 2024)
Investor deck · 22 slides · November 2024
- Investor Presentation (September 2024)
Investor deck · 22 slides · September 2024
- IPO Roadshow (July 2024)
IPO roadshow · 27 slides · Jul 23, 2024
- Investor Presentation (July 2024)
Investor deck · 24 slides · July 2024
- IPO Roadshow (June 2024)
IPO roadshow · 25 slides · Jun 11, 2024